The estimated Net Worth of Barry Labinger is at least $1.68 Million dollars as of 13 November 2015. Barry Labinger owns over 3,376 units of Checkmate Pharmaceuticals stock worth over $264,411 and over the last 11 years Barry sold CMPI stock worth over $1,410,755.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Sign up
Barry Labinger CMPI stock SEC Form 4 insiders trading
Barry has made over 2 trades of the Checkmate Pharmaceuticals stock since 2015, according to the Form 4 filled with the SEC. Most recently Barry sold 3,376 units of CMPI stock worth $123,224 on 13 November 2015.
The largest trade Barry's ever made was selling 36,126 units of Checkmate Pharmaceuticals stock on 11 November 2015 worth over $1,287,531. On average, Barry trades about 4,938 units every 0 days since 2013. As of 13 November 2015 Barry still owns at least 25,182 units of Checkmate Pharmaceuticals stock.
You can see the complete history of Barry Labinger stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
What's Barry Labinger's mailing address?
Barry's mailing address filed with the SEC is C/O CHECKMATE PHARMACEUTICALS, INC., 245 MAIN STREET, 2ND FLOOR, CAMBRIDGE, MA, 02142.
Insiders trading at Checkmate Pharmaceuticals
Over the last 4 years, insiders at Checkmate Pharmaceuticals have traded over $15,801,789 worth of Checkmate Pharmaceuticals stock and bought 928,470 units worth $13,457,615 . The most active insiders traders include Holdings A/S Novo, Global Strategic Fund Ii L...., and Michael Powell. On average, Checkmate Pharmaceuticals executives and independent directors trade stock every 27 days with the average trade being worth of $1,077,132. The most recent stock trade was executed by Global Strategic Fund Ii L.... on 13 May 2022, trading 131,650 units of CMPI stock currently worth $1,375,743.
What does Checkmate Pharmaceuticals do?
Checkmate Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing novel therapeutics for the treatment of cancer. It develops CMP-001, which is in phase II clinical trial in combination with pembrolizumab to treat patients with PD-1 refractory melanoma; combination with nivolumab to treat patients with PD-1 naïve neoadjuvant melanoma; and treatment in patients with PD-1 refractory melanoma. The company has strategic alliances with Merck KGaA and Pfizer. Checkmate Pharmaceuticals, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
What does Checkmate Pharmaceuticals's logo look like?
Complete history of Barry Labinger stock trades at Emergent Biosolutions Inc and Checkmate Pharmaceuticals
Checkmate Pharmaceuticals executives and stock owners
Checkmate Pharmaceuticals executives and other stock owners filed with the SEC include:
-
Dr. James E. Wooldridge M.D.,
Chief Medical Officer -
Dr. Kleem Chaudhary Ph.D.,
Chief Bus. Officer -
Alan Fuhrman,
Interim CEO, Pres & Director -
Dr. Arthur M. Krieg,
Founder, Chief Scientific Officer, Treasurer, Sec. & Independent Director -
Katherine A. Eade,
Gen. Counsel -
Robert F. Dolski,
CFO & Principal Accounting Officer -
Arthur M Krieg,
Chief Scientific Officer -
Joy Yan,
Director -
Holdings A/S Novo,
10% owner -
Barry Labinger,
President and CEO -
Kleem Chaudhary,
Chief Business Officer -
Karen Brennan,
Chief Operating Officer -
Global Strategic Fund Ii L....,
-
Michael Sofinnova Venture P...,
-
Michael Powell,
Director -
Keith T. Flaherty,
Director -
Oren Isacoff,
Director -
Peter Colabuono,
Director -
Robert Dolski,
Chief Financial Officer -
Alan Fuhrman,
Director -
Jon Marc Wigginton,
Director -
Alan Bash,
Chief Executive Officer